Efficacy and Safety Study of Benralizumab for Patients with Severe Nasal Polyposis

Trial Identifier: D3252C00001
Sponsor: AstraZeneca
NCTID:: NCT03401229
Start Date: January 2018
Primary Completion Date: July 2020
Study Completion Date: July 2020

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English version
Danish Translation
Dutch Translation
French Translation
French Translation
German Translation
German Translation
German Translation
Hungarian Translation
Polish Translation
Spanish Translation

Trial Locations